Characterizing FDA’s Approach to Benefit-Risk Assessment Throughout the Medical Product Life Cycle; Public Meeting; Request for Comments

1 organizations filed 1 public comment on Characterizing FDA’s Approach to Benefit-Risk Assessment Throughout the Medical Product Life Cycle; Public Meeting; Request for Comments, at the Food and Drug Administration. The comment window closed 2598d ago.

Commenters (1)

• Consumer Healthcare Products Associationtrade assoc.

  1 filing · confidence 97%